It is now widely known that erythropoietin (Epo) does not only affect the haematopoietic system, but it can be considered a multifunctional trophic factor with an effect on the general homoeostasis of the entire organism. The recent discovery of a specific Epo/Epo-receptor system in the central nervous system (CNS) and cerebrospinal fluid, independently of the haematopoietic system, has further paved the way for new studies aimed at investigating the different sites of cerebral expression of Epo and its receptor, the regulation of their expression and, finally, the effects that this hormone has on the development and maturation of the brain. A further aim has been to investigate how it influences CNS homoeostasis and neurotransmission in adult brain. Attention has also been focused on the neurotrophic and neuroprotective function of Epo in different conditions of neuronal damage, such as hypoxia, cerebral ischaemia and subarachnoid haemorrhage, and therefore on the possibility that human recombinant Epo therapy could soon be used in clinical practice, also to limit neuronal damage induced by these diseases.
INTRODUCTION
It was once believed that erythropoietin (Epo) affected erythroid cells only, and that it triggered their proliferation and differentiation by binding to a specific membrane receptor (EpoR). However, since recombinant Epo and EpoR became available, many experimental and clinical studies have been performed, showing that Epo is a multifunctional trophic factor, has different sites of expression, a tissue-specific regulation and several mechanisms of action. Functional receptors for Epo, in fact, have been found in non-erythroid blood cell lines, such as myeloid cells, lymphocytes and megakariocytes, and also in a wide variety of non-haematopoietic cells, such as endothelial cells, mesangial, myocardial and smooth muscle fibre cells and cells of neural origin. On the other hand, as well as the liver and the kidney, which are the major Epo-producing sites in fetal and adult life respectively, another two sites of Epo production have been identified : the uterus and the brain, in which the expression of Epo seems to be regulated in a tissuespecific manner [1] . Since Epo and its receptor are produced in the central nervous system (CNS) and Epo does not cross the normal blood-brain barrier (BBB), several authors suggest that Epo has a paracrine function. In recent years, several studies have been undertaken with a view to clarifying the impact of Epo and EpoR expression in the brain during fetal and adult life [2] .
Figure 1 The Epo/EpoR system in the brain
Epo and EpoR expression change significantly during brain development, thus indicating the importance of the Epo\EpoR system in neurodevelopment. Morever, the hypoxia-responsive production of Epo found in the adult brain suggests it may act as a neurotrophic and neuroprotective factor after brain injury. Finally, the Epo-induced release of neurotransmitters suggests that the hormone can directly or indirectly influence neurotransmission ( Figure 1 ).
The present review considers the data available on the impact of Epo on brain function in order to provide an overview of current knowledge, and to indicate the lines of new research that should be undertaken to establish whether the neuroprotective function of Epo may be exploited, perhaps in clinical practice. Masuda et al. [3] first demonstrated the presence of EpoR in two rodent cell lines of neural origin, PC12 (clonal pheochromocytomic) and SN6 (septal cholinergic) cells. These authors [3] also demonstrated in vitro that astrocytes produced Epo, the expression of which is greatly enhanced by hypoxia, by regulation at the level of mRNA. Brain Epo is smaller in size (30.3 kDa versus 30.5 kDa) and more active in vitro at lower concentrations than recombinant Epo. These differences appear to be due to the different extent of sialylation of brain Epo. The observation that Epo is produced by astrocytes and then binds to the EpoR on adjacent neurons suggests that Epo can affect neurons in a paracrine and autocrine fashion, independently of the endocrine erythropoietic system, since the intact BBB seems to preclude the passage of kidney-derived circulating Epo [2, 4] . Specific Epo-binding sites have been identified in specific areas of the adult mouse brain [5] , and in primary cultures of rat hippocampal and neocortex neurons [6] . Epo and its receptor have been localized in specific areas of the embryonic, fetal and adult brain of rats, monkeys and humans. Epo and EpoR mRNA have been identified in biopsies of the temporal cortex, the hippocampus, cerebellum and amygdala, and their expression is increased after exposure to low O # levels, as occurs in vivo in the brain of mice with induced anaemia [7, 8] . It has been shown that Epo and EpoR expression change significantly during neurodevelopment. High EpoR expression has been found in embryonic mouse neural tissue and brain, reaching levels similar to that observed in adult bone marrow. This expression decreases significantly during development and maturation of the brain, by up to 100-fold after birth.
EXPRESSION AND REGULATION OF EPO AND EPOR IN NEURAL CELLS AND THE BRAIN: ROLE IN NEURODEVELOPMENT
EpoR expression in the neural tube may be the origin of the EpoR detected in the brain during development. Furthermore, the distribution of Epo and EpoR in the CNS changes as gestational age increases [9] . Juul et al. [10, 11] evaluated Epo and EpoR distribution in human brains from 5 weeks after conception through fetal development to adulthood, using a combination of reverse-transcriptase PCR and immunohistochemistry. mRNA for Epo and EpoR was detected as early as the fifth week post-conception. At 5 and 6 weeks, a preponderance of Epo and EpoR staining was noted in the undifferentiated neuroepithelial cells of the periventricular zone, which is the germinal zone for nascent neurons. As development progressed, the pattern of expression of the two proteins changed. At 10 weeks, Epo was present throughout the cortical wall, the most intense immunoreactivity being present in the ventricular and subventricular zones. EpoR on the other hand, was localized mainly in the subventricular zone, which contains multipotent cells that develop into oligodendrocytes and astrocytes. As neurodifferentiation progressed, EpoR staining began to localize predominantly to astrocytes, whereas Epo localized primarily in neurons. These findings are not in agreement with those reported in murine models, which suggest that EpoR is mainly present in neurons, whereas Epo is expressed by astrocytes. However, in postnatal and adult human brains, both astrocytes and neurons were immunoreactive with antibodies to EpoR and Epo. Epo and EpoR expression were also found in other cell types, such as Cajal-Retzius neurons and cells of the choroid plexus. The quantity of EpoR in adult human brain is 30-fold less than that found in haematopoietic tissue, and this is comparable with values described in mice. The presence of Epo and its receptor in the developing brain, and their persistence in the mature brain, suggest that they play a role in both neurodevelopment and brain homoeostasis [12] [13] [14] .
In a model of knockout mice for Epo and EpoR, death occurs on around embryonic day 13.5, due to erythropoietic failure in the fetal liver. However, these mice had other organ abnormalities, such as ventricular hypoplasia and increased apoptosis in fetal liver, heart and brain. Recently, Yu et al. [15] demonstrated that these defects can be corrected in animals expressing the EpoR transgene, and stressed the importance of the Epo\EpoR system during ontogenesis.
Chin et al. [16] showed that low O # levels and anaemia up-regulate EpoR expression in the brain, and demonstrated in vitro that hypoxia induces EpoR synthesis in NT2 (human neuronal precursor cell lines) culture cells, without stimulating cell proliferation. The addition of Epo under hypoxia to the medium restored cell growth to, or above, the level observed in the absence of low O # tension. Thus hypoxia in vitro and anaemic stress in vivo induce both Epo and EpoR expression and probably enhance the sensitivity of EpoR to Epo [16] .
The immunohistochemical positivity of neurons for Epo suggests that neuronal cells can also produce Epo. In 1998, Juul et al. [17] suggested that not only astrocytes, but also neurons produce Epo. In 2000, Bernaudin et al. [18] demonstrated for the first time that neuron cell cultures, obtained from OF1 mouse embryos, express Epo mRNA, and that this expression is greatly enhanced by hypoxia, whereas it is completely prevented by cycloheximide, an inhibitor of protein synthesis. These authors [18] suggested that an O # -sensing system, similar to that identified in hepatoma cell lines and the kidney, may control Epo production in both astrocytes and neurons, and showed in vitro and in vivo that not only hypoxia, but also desferrioxamine and CoCl # , two agents known to mimic the hypoxic induction of Epo in hepatoma cells, can induce Epo mRNA expression in astrocytes and neurons. Therefore, as with Epo production in the kidney and the fetal liver, the effect of hypoxia on Epo production in neuronal cells is regulated in part via the transcriptional activator hypoxia-inducible factor-1 (HIF-1). Treatment with H # O # or agents stimulating its production inhibits the activation of HIF-1 and hypoxia-induced Epo production [19] .
Hypoxia may not be the only relevant stimulus for brain Epo production. Other metabolic disturbances, such as hypoglycaemia or strong neuronal depolarization that generate mitochondrial reactive oxygen species, may increase cerebral Epo expression through HIF-1 activation [20] . Furthermore, Epo mRNA expression by cultured astrocytes is stimulated by insulin and insulinlike growth factors in a dose-dependent manner. Insulin and insulin-like growth factors are abundantly expressed in the CNS, but the physiological importance of their stimulatory effect on Epo production in the brain has yet to be studied [21] .
EPO IN THE CEREBROSPINAL FLUID (CSF)
The choroid plexus is immunoreactive for both Epo and EpoR during development and after birth. Because it is the primary site of CSF production, several authors have investigated whether Epo is present in the spinal fluid. In a study conducted on 50 human newborns [22] , 25 of whom were treated with human recombinant Epo (rHuEpo), Epo was found in the CSF of normal pre-term and full-term infants, decreasing proportionately according to gestational age. No differences were found between the CSF Epo concentrations of neonates treated with rHuEpo and controls, despite significantly increased plasma Epo concentrations [22] . This suggests that Epo does not cross the intact BBB, as suggested by its size and glycoprotein structure. Low concentrations of Epo are also found in the CSF of normal human adults [22] . Studies have been undertaken to ascertain whether CSF Epo concentrations change in conditions of neural injury, such as hypoxia, meningitis or intraventricular haemorrhage, and whether this change reflects loss of BBB integrity or increased CNS Epo production. The results available on this aspect are contradictory. Some authors believe that the production of Epo in CSF is stimulated in conditions of neural injury. Juul et al. [23] , for example, demonstrated that Epo concentration in the CSF was significantly higher in newborns with asphyxia or intraventricular haemorrhage than in controls, and this increase was related to an increased CNS synthesis of Epo, rather than any passage through the BBB. Marti et al. [2] observed that Epo was present in the CSF of five patients with traumatic brain injuries, and found no correlation between the concentration of Epo in serum and that in CSF. Nor did the intravenous administration of rHuEpo increase Epo levels in the CSF of patients with cerebral tumours [24] .
However, Brines et al. [25] reported that rHuEpo may cross the BBB, this passage increasing in conditions of neural injury. Although the BBB is considered impermeable to large molecules, recent studies clearly demonstrate that some high-molecular-mass molecules can be specifically transported into the brain across the capillary endothelium. Two different types of EpoR have been found in the cerebral capillary endothelium [26] . It has therefore been suggested that circulating Epo could bind to these receptors, which are present on the luminal surfaces of the endothelial cells. This would initiate endocytosis, followed by translocation into the brain. If so, systemically administered rHuEpo could directly reach the brain, providing protection against brain injury.
Finally, it has been shown that CSF Epo concentrations in patients with depression are higher than those in healthy controls, this difference being resolved following antidepressant therapy [27] . The significance of these findings is unclear. One hypothesis put forward is that the brain of patients with depression may be in a state of hypoxia, which induces Epo production.
There is also evidence that Epo induces indirect biohumoral variations in the CSF ; the diminished Na + concentrations found in the CSF suggest that Epo can directly or indirectly interfere with the mechanism of CSF production, which is a Na + -dependent process. Also, variations in the CSF pH after acute infusion of rHuEpo may play an important part in the neuroprotective effects identified in vitro, because local modifications in the acid-base balance may interfere with communication and cellular neurotransmission [24, 28, 29] .
EPO AS A NEUROTROPHIC AND NEUROPROTECTIVE FACTOR
It is known that rHuEpo therapy in uraemic patients has a benefical effect on quality of life, normalizing the haematocrit, restoring and regularizing the menstrual cycle in women, and reducing prurigo [30] . rHuEpo treatment also improves brain function, as shown by findings from neuropsychological tests and electrophysiological measurements [31] . This improvement is correlated with a progressive increase in the haematocrit level and therefore with the correction of the hypoxic state of the brain. If anaemia is corrected, and the haematocrit levels return to normal, a further improvement in neurocognitive function may be achieved [32] . However, several studies in vitro and in vivo have shown that Epo could have a direct neurotrophic and neuroprotective effect. The expression of the Epo\EpoR system in particular areas containing neurons vulnerable to ischaemic insult, such as the hippocampus and the cerebral cortex, the regulation of its expression during fetal development and finally the induction of both Epo and EpoR gene expression by hypoxia, suggest that Epo could act on the CNS as a neurotrophic and neuroprotective factor, particularly in conditions of neural damage, such as hypoxia, ischaemia or brain haemorrhage. Moreover, it has been shown that Epo could influence the release of neurotransmitters, playing an important role in synaptic plasticity in the adult brain.
Konishi et al. [33] demonstrated first that some haematopoietic factors, including Epo, act as neurotrophic factors on central cholinergic neurons, influencing their differentiation and regeneration. rHuEpo prolongs the survival of rats with cholinergic-septal neuronal lesions produced by fimbria-fornix transactions in vivo, and it increases the choline-acetyltransferase activity of neurons in vitro [34] . Campana et al. [35] have identified a 17-amino-acid sequence present in Epo, which has a neurotrophic activity in vitro and in vivo, but has no erythropoietic activity. These authors [34] demonstrated that both Epo and the epopeptide AB, a synthesized peptide containing the amino-acid sequence mentioned above, induce differentiation, increase choline-acetyltransferase activity and prevent cell death in both murine NS20Y and human SK-N-MC neuroblastoma cell lines. Epo and the epopeptide AB act through the EpoR, enhancing the phosphorylation of the mitogen-activated protein kinase (MAPK) and inducing tyrosine phosphorylation of Janus kinase 2 ( JAK2). Furthermore, subcutaneous injection of Epo and epopeptide AB into mice was found to induce motor and plate sprouting in adjacent muscles.
Many experimental studies have shown that Epo has a neuroprotective effect during cerebral ischaemia. It has been demonstrated that glutamate is the main factor responsible for neuronal death associated with hypoxia or hypoglycaemia, or both (ischaemia) [36, 37] . The rapid increase in the extracellular glutamate concentration in the CNS in specific cerebral regions, after the onset of cerebral ischaemia, is proportionate to the severity of ischaemia itself [36] . A massive and sustained increase in the intracellular Ca# + concentration, evoked by activation of glutamate-induced N-methyl-D-aspartate receptors, plays a critical role in determining the intracellular enzymic cascade leading to neuronal death [38] .
In 1997, Morishida et al. [6] showed that Epo pretreatment of cultured neurons prevented glutamateinduced cell death in a dose-dependent manner : a very short incubation period with Epo (5 min or less) can induce a neuroprotective effect against glutamate toxicity, although a relatively long incubation period (8 h) is required for the cells to become resistant to glutamate. This finding probably indicates that protection is partly dependent on RNA and protein synthesis. In a model of cerebral ischaemia in vitro, comprising hypoxia and glucose deprivation, Sinor et al. [39] recently showed that Epo (30 pM) protects cultured neurons, but not astrocytes, from death. Morever, Epo can reduce the excitotoxic effect of cortical neuron cultures treated with glutamate or glutamate-receptor agonists [39] . It is not yet known whether Epo has a neuroprotective effect when administered simultaneous to the onset of hypoxia. Recently, Lewczuk et al. [40] demonstrated that Epo treatment of cultured hippocampal neurons from newborn rats at the onset of hypoxia, can prevent neuronal death. Interestingly, in this study [40] it was found that Epo and EpoR mRNA are not constitutively expressed in the adult brain, but their expression is rapidly induced by hypoxia. A constitutive expression of Epo and EpoR has been described only during the early stages of brain development. In 1998, Sadamoto et al. [41] demonstrated in an animal model of cerebral ischaemia that Epo ameliorates place-navigation disability, cortical infarction and thalamic degeneration in rats with permanent middle cerebral artery occlusion. Using in situ hybridization, the authors [41] also found that EpoR mRNA was up-regulated in the periphery of the cerebrocortical infarction, the so-called ischaemic penumbra. This finding suggests that an increased number of EpoR in neurons facilitates Epo signal transmission, limiting the extent of damage. In 1998, using lateral ventricular infusion of soluble EpoR in an experimental model of cerebral ischaemia in the gerbil, Sakanaka et al. [42] demonstrated that Epo ameliorates neuron survival. In other words, the administration of EpoR potentiates Epo activity, improving neuronal survival. In 1999, Bernaudin et al. [43] showed the potential role of Epo in focal permanent cerebral ischaemia induced in mice by permanent occlusion of the left middle cerebral artery. Mice treated with intraventricular injection of recombinant mouse Epo presented a significant reduction in infarction volume. These findings confirm that Epo plays a role in the brain response to ischaemia, and it may be of therapeutic value in patients with stroke [44] . Here, it is important to establish whether or not systemically administered rHuEpo can cross the BBB, since intrathecal administration is an impractical approach in most clinical settings. Brines et al. [25] and Cerami et al. [45] agree that this hormone can cross the BBB. In a recent study [45] , it was demonstrated that systemically administered epoetin-α crossed the BBB and significantly reduced tissue damage in an ischaemic stroke animal model, even when it was administered 6 h after the induction of stroke.
More recently, the neuroprotective effect of Epo was observed in cases of neuronal lesions from subarachnoid haemorrhage (SAH). It is well known that acute vasoconstriction and altered cerebrovascular reactivity frequently follow SAH, and are important causes of cerebral ischaemia and early death [46, 47] . Asano et al. [48] and Nagai et al. [49] have also reported microcirculatory disturbances in experimental models of SAH. The constriction of the intraparenchymal vessels may depend on several mechanisms. Vasoconstriction may be actively induced by spasmogenic substances released from subarachnoid clots [50] , or may be the consequence of an imbalance between endothelial-derived relaxing factors, the most important substances being NO, and the socalled endothelial-derived contracting factors, the most potent of which is endothelin [51] [52] [53] . It has been reported that NO level decreases acutely within 10 min after SAH, leading to cerebrovascular relaxation impairment and ischaemic neuronal damage [54] . In an animal model, Buemi et al. [55] recently reported that rHuEpo administration immediately after experimental SAH effectively reduced the mortality rate and enhanced functional recovery. The authors showed that all rHuEpotreated rabbits (100 %) survived for at least 72 h, whereas 42.9 % of SAH plus placebo group died within 72 h. An open-field test performed at 24 h, 48 h and 72 h after SAH, demonstrated an increase in locomotor activity at 72 h in the placebo-treated group, whereas no increase in locomotor activity was observed in rHuEpo-treated rabbits. These findings demonstrated that Epo has a neuroprotective effect in SAH ; it can attenuate acute vasoconstriction, thus preventing ischaemic damage in the brain. Alafaci et al. [56] also demonstrated that Epo has a neuroprotective effect in SAH, because it can attenuate acute vasoconstriction and prevent brain ischaemic damage. In fact intraperitoneal administration of rHuEpo at a dose of 1000 units\kg significantly reversed the vasoconstriction (30 % compared with control) of the basilar arteries, which was confirmed by the low wrinkle's degree of the internal elastic lamina. Histological analysis performed 24 h after SAH showed a reduction in brain ischaemic damage in animals given rHuEpo. In particular, analysis of cortical neurons showed that animals treated with rHuEpo presented a significant decrease in the amount of necrotic neurons compared with the untreated animals. These encouraging findings should be confirmed in man, with a view to utilizing rHuEpo in clinical practice to prevent or, at least limit, neuronal damage from ischaemia. Epo may reverse acute vasoconstriction and reduce ischaemic neuronal damage by enhancing the endothelial release of NO during the early stages of SAH. This hypothesis is supported by findings in three recent studies, which demonstrated an acute decrease in cerebral NO levels after SAH [54] , and a significant improvement in NO synthase activity following the administration of rHuEpo [57, 58] . Moreover, rHuEpo may act directly on cerebral arteries by binding to specific endothelial receptors, thus exerting a competitive effect in the control of the cerebrovascular tone [59] .
Epo may also be involved in synaptic plasticity via the inhibition or stimulation of various neurotransmitters. The data available on this aspect are, however, contradictory. Koshimura et al. [57] propose that Epo stimulates dopamine (DA) release and tyrosine hydroxylase activity in PC12 cells, through the activation of Ca# + channels, and that it also increases NO synthesis. Since NO is reported to stimulate the release of different neurotransmitters, such as γ-aminobutyric acid, DA and acetylcholine, they suggested that Epo may also partly stimulate neurotransmitter release by inducing NO production. However, Yamamoto et al. [60] demonstrated that Epo stimulates the release of DA and acetylcholine from hippocampal and striatal slices in rats, but this occurred independent of NO production. On the other hand, Kawakami et al. [61] showed that Epo and the Epo mimetic peptide 1, an EpoR agonist, inhibit the Ca# + -induced release of DA from PC12 cells, by activating JAK2, which is known to be linked with EpoR. For example, the discrepancy may depend on several factors. In a study by Kaplan and Miller [62] , DA release was shown to occur in differentiated PC12 cells in the presence of the nerve growth factor, which is known to induce significant changes in signal transduction pathways. Another cause of this discrepancy might be the heterogeneity of PC12 cells.
At present, the mechanisms and the signal pathways by which Epo acts as a neuroprotective and neurotrophic agent in the CNS are not well understood, and several theories have been proposed. Morishida et al. [6] and Koshimura et al. [57] have suggested that many functions of Epo in the brain may be mediated by activation of Ca# + channels [63] . The addition of Epo to PC12 neuronal cells results in an increase of intracellular Ca# + and monoamine concentrations [3] . In 1999, Koshimura et al. [57] suggested that Epo may activate Ca# + channels by inducing membrane depolarization in neuronal cells and noted that Epo stimulated MAPK activity, thus suggesting that Epo induces various neural responses via the activation of Ca# + channels and MAPK activity, protecting, for example, neurons from glutamate toxicity, DA release and NO synthesis. Recently, Assandri et al. [64] demonstrated that Epo stimulates the activity of Ttype voltage-dependent Ca# + channels, and Miller et al. [65] identified the EpoR domain required for Ca# + -channel activation. Sakanaka et al. [42] have observed that Epo, similar to platelet-derived growth factor, may increase the activity of antioxidant enzymes, such as superoxide dismutase, glutathione peroxidase and catalase, in neurons, thus protecting the brain parenchyma from ischaemic damage. Sasaki et al. [66] and Calapai et al. [44] suggest that the Epo may exert its neuroprotective action by reducing the NO-mediated formation of free radicals or by antagonizing their toxicity. Recently, Digicaylioglu et al. [67] have shown that the binding of Epo to its receptor induces the activation of JAK2, leading to phosphorylation of the inhibitor of nuclear factor-κB, subsequent translocation of the transcription factor nuclear factor-κB from the cytoplasm to the nucleus and eventually transcription of neuroprotective genes. Another theory, proposed by Yamaji et al. [26] and Marti et al. [68] , is that Epo may modulate angiogenesis in the ischaemic brain, thus improving the blood flow and tissue oxygenation in the border zone of the ischaemic area. It has been observed that Epo, similar to other growth factors, such as granulocyte colonystimulating factor and granulocyte\macrophage colonystimulating factor, can stimulate endothelial proliferation and, in turn, new vessel formation both in vitro and in vivo [69] . Previously, Bernaudin et al. [43] have shown that Epo may reduce the brain ischaemic area by protecting endothelial and neural cells from apoptotic cell death. In a recent study, Sire' n et al. [70] showed in rats with middle cerebral artery occlusion that, 24 h after intraperitoneal administration at 5000 units\kg of body mass, rHuEpo dramatically reduces the infarction area. Moreover, the activation of extracellular signal-regulated kinases and protein kinase Akt-1\protein kinase B, Epo (0.3 units\ml) inhibits the apoptosis of hippocampal neurons [70] . The neuroproperties of Epo may then result from the activation of signal-transduction pathways, such as those employing JAK2\signal transduction and activators of transcription-5a\5b, Ras\MAPK or phosphatidylinositol 3-kinase\protein kinase Akt [39] . Finally, Epo may control the synthesis of neuroglobin, a new identified globin expressed mainly in the brain, which can fix O # . Epo may contribute to improving the uptake and availability of O # in the neural cells by means of this mechanism [71] .
In conclusion, the discovery of the production of Epo by neuronal cells in man was made only 10 years ago. Yet, now an important body of evidences demonstrates the impact of this hormone in the pathophysiology of the brain. Treatment with rHuEpo has perhaps definitively underscored the neurotrophic and protective effect of the hormone, thus opening new frontiers in the treatment of diseases of the CNS.
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